One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent
Authors:
Open Access
- 1 February 2014
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 113 (4) , 613-620
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
This publication has 14 references indexed in Scilit:
- Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in ChinaJACC: Cardiovascular Interventions, 2013
- Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World PracticeJACC, 2013
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionJACC, 2011
- A New Era of Prospective Real-World Safety EvaluationJACC: Cardiovascular Interventions, 2011
- Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trialThe Lancet, 2011
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010
- Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificityEuroIntervention, 2010
- Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical PracticeJACC: Cardiovascular Interventions, 2009
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Guidelines for Percutaneous Coronary InterventionsEuropean Heart Journal, 2005